3 Cryptos to Buy for 2022
Is your crypto portfolio ready for 2022?

With Bitcoin hitting all-time highs, now is the time to reorient your crypto plays for the coming year.

That's why Luke Lango, InvestorPlace's resident crypto expert is releasing his latest calls… completely free.

You can get them in his latest report, "3 Cryptos to Beat Bitcoin."
Just click here to claim your copy today.
Alexander R. Mackenzie, insider at Pfizer
Alexander R. Mackenzie Insider Alerts

Get notified the next time Alexander R. Mackenzie buys or sells Pfizer stock. Enter your email address below to get our daily insider buying and selling report.

Alexander R. Mackenzie Insider Information

EVP of Pfizer
Rod MacKenzie, PhD, is Chief Development Officer and Executive Vice President for Pfizer. Rod leads the Global Product Development organization, which is responsible for the clinical development and advancement of Pfizer’s pipeline of innovative medicines in inflammation and immunology, internal medicine, hospital, oncology and rare disease, as well as regulatory affairs in support of Pfizer’s R&D pipeline and portfolio of marketed therapies. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximizing the return on R&D investment across the Pfizer portfolio, and is a member of Pfizer’s Executive Leadership Team.

Rod joined Pfizer in Sandwich, UK as a Research Scientist and conducted medicinal chemistry research in the cardiovascular, GI, Sexual Health, Urology and Allergy & Respiratory diseases. Rod is the co-inventor of darifenacin (Enablex™).

Rod has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development where he oversaw the Cardiovascular & Metabolic Diseases, Pain & Sensory Disorders and Neuroscience Research Units and was responsible for all medicinal chemistry at Pfizer, as well as Small Molecule Pharmaceutical Sciences, Pharmacokinetics, Dynamics & Metabolism and Comparative Medicine. He also served as Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global R&D facility. Prior to this role, Rod held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, U.K., Head of the Discovery Technology Center in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety R&D.

Rod represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV. He also represents Pfizer as Vice Chair on the Board of Directors for TransCelerate, a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies, as well as on the Board of Directors for The National Health Council, an organization that brings together all segments of the health community to forge consensus and drive patient-centered health policy. Rod is also a member of the Executive Committee for Clinical Trials Transformation Initiative, a public-private partnership co-founded by FDA and Duke University to develop and drive practices that will increase the quality and efficiency of clinical trials. In recognition of his long-time advocacy for the advancement of women in the healthcare industry, Rod was named Healthcare Businesswomen’s Association 2020 Honorable Mentor.

Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition with Professor W.C. Still.

What is Alexander R. Mackenzie's net worth?

The estimated net worth of Alexander R. Mackenzie is at least $4.33 million as of June 20th, 2019. Dr. Mackenzie owns 80,094 shares of Pfizer stock worth more than $4,329,081 as of January 20th. This net worth estimate does not reflect any other assets that Dr. Mackenzie may own. Learn More.

How do I contact Alexander R. Mackenzie?

The corporate mailing address for Dr. Mackenzie and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323.

Has Alexander R. Mackenzie been buying or selling shares of Pfizer?

Alexander R. Mackenzie has not been actively trading shares of Pfizer during the past quarter. Most recently, Alexander R. Mackenzie sold 41,360 shares of the business's stock in a transaction on Thursday, December 2nd. The shares were sold at an average price of $54.26, for a transaction totalling $2,244,193.60.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Jennifer Damico (SVP), Jennifer Damico (SVP), Douglas Lankler (EVP), Alexander Mackenzie (EVP), and John Young (Insider).

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 238,021 shares worth more than $12,217,419.90. The most recent insider tranaction occured on December, 2nd when EVP Alexander R Mackenzie sold 41,360 shares worth more than $2,244,193.60. Insiders at Pfizer own 0.1 % of the company.

Information on this page was last updated on 12/2/2021.

Alexander R. Mackenzie Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2021Sell41,360$54.26$2,244,193.60View SEC Filing Icon  
6/20/2019Sell30,000$44.00$1,320,000.0080,094View SEC Filing Icon  
4/1/2019Sell15,000$42.83$642,450.00124,994View SEC Filing Icon  
8/3/2018Sell25,642$39.51$1,013,115.42127,954View SEC Filing Icon  
12/15/2017Sell6,750$37.00$249,750.00103,458View SEC Filing Icon  
11/1/2017Sell14,700$35.30$518,910.00117,432View SEC Filing Icon  
10/2/2017Sell7,350$35.65$262,027.50117,432View SEC Filing Icon  
9/1/2017Sell7,350$34.00$249,900.00124,774View SEC Filing Icon  
8/31/2017Sell7,350$34.00$249,900.00132,124View SEC Filing Icon  
8/7/2017Sell15,000$33.50$502,500.00151,474View SEC Filing Icon  
See Full Table

Alexander R. Mackenzie Buying and Selling Activity at Pfizer

This chart shows Alexander R Mackenzie's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More

Today's Range

Now: $54.05
Low: $53.07
High: $54.52

50 Day Range

MA: $54.75
Low: $49.60
High: $61.25

2 Week Range

Now: $54.05
Low: $33.36
High: $61.71

Volume

34,833,765 shs

Average Volume

37,716,852 shs

Market Capitalization

$303.38 billion

P/E Ratio

16.09

Dividend Yield

2.91%

Beta

0.69
Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!